Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 3151 shares changing hands. The stock had previously closed at C$0.09.
Resverlogix Stock Performance
The company has a debt-to-equity ratio of -82.47, a current ratio of 0.04 and a quick ratio of 0.04. The company has a market capitalization of C$29.26 million, a price-to-earnings ratio of -2.12 and a beta of -0.11. The business’s 50-day moving average price is C$0.10 and its two-hundred day moving average price is C$0.10.
Resverlogix Company Profile
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Featured Articles
- Five stocks we like better than Resverlogix
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
